Financial Performance - The Group recorded a consolidated revenue of approximately RMB 13,090,000 for the year ended 31 December 2022, representing an 84.34% decrease from approximately RMB 83,601,000 in 2021[21] - The Group reported a loss before taxation of approximately RMB 15,826,000 for 2022, compared to a profit before taxation of approximately RMB 42,521,000 in 2021[22] - The basic and diluted loss per share for 2022 was RMB 1.59 cents, compared to earnings per share of RMB 3.65 cents in 2021[22] - The Group's reserves available for distribution as of December 31, 2022, amounted to approximately RMB 18,775,000, down from approximately RMB 34,150,000 in 2021[87] - The Board does not recommend the payment of any dividend for the year ended December 31, 2022, consistent with the previous year[81] Assets and Liabilities - Total assets decreased to approximately RMB 178,625,000 in 2022 from RMB 194,325,000 in 2021, while total liabilities slightly decreased to RMB 36,742,000 from RMB 38,753,000[21] - The Group's net current assets were approximately RMB 140,484,000 as of 31 December 2022, down from RMB 154,022,000 in 2021[27] - The gearing ratio remained at 0% as of 31 December 2022, indicating no borrowings during the year[28] - As of December 31, 2022, the Group's total banking facilities amounted to nil, indicating no charge on assets[48] Operational Challenges and Strategies - The management faced significant challenges due to the COVID-19 pandemic and strict pharmaceutical market regulations but managed to maintain operations without large-scale layoffs[32] - The Group aims to strengthen its professional capacity building in response to the downward pressure in the domestic drug market[33] - The Group plans to raise further funds through bank loans, issuance of new shares, convertible notes, and new debts to support future development[29] Research and Development - The Group has established five major specialty brands focusing on brain science, allergies, and viruses, with a core strategy of building a R&D-based digital health care system[34] - The Group's big data platform for precision medicine enhances clinical research capabilities, aiming to replace traditional CSO models with digital clinical research[35] - The Group's "Research-based Therapy RWS-Therapy Model" and "Digital clinical research-based promotion D-CRCO model" redefine treatment and commercialization approaches in the healthcare sector[36] - The Group's Xien Brain Digital Clinical Research Center has participated in or organized over 60% of major national clinical studies in brain science[41] - The Group's "RWS Wanquan Center" aims to re-screen existing drugs using big data to discover optimal treatments for various diseases[42] - The Group has established digital medicine clinics in major cities, collaborating with top medical institutions to enhance healthcare services[43] Shareholder Information - As of December 31, 2022, the total number of shares held by the Chairman, GUO Xia, is 132,851,941, representing 13.35% of the total shares[92] - Winsland Agents Limited holds 349,368,873 shares, accounting for 35.10% of the total issued shares[94] - The total number of share options as at 31 December 2022 was 25,380,000 after accounting for lapsed and cancelled options[112] - The Share Option Scheme allows for the issuance of up to 10% of the total shares in issue on the adoption date, with 88,947,166 shares available for issuance under the scheme, representing approximately 8.94% of the total issued shares[106] Corporate Governance - The Company has complied with relevant laws and regulations, with no material breaches reported during the year[79] - The Company has complied with the Corporate Governance Code for the year ended 31 December 2022, with the exception of not having a Chief Executive Officer appointed[145] - The Company has established three committees: audit committee, nomination committee, and remuneration committee to oversee specific aspects of its affairs[165] - The Nomination Committee is responsible for nominating suitable candidates for the Board, ensuring a balance of skills, experience, and diversity[178] - The selection criteria for candidates include character, qualifications, experience, commitment, and independence as per GEM Listing Rules[179] Risk Management - The Group has implemented a sound risk management and internal control system, with ongoing reviews by the Board and Audit Committee[198] - An external independent consultant was engaged to review the internal control system of the Group during the year[198] - The risk management process includes identifying risks, assessing risk levels, and implementing risk management solutions[199] - The Group maintains a risk register to track identified risks and their responses, ensuring effective internal control procedures[200] Stakeholder Engagement - The Company maintains communication with stakeholders through various channels to understand their views and needs[74] - The Group's environmental and social strategies are monitored by dedicated managerial staff and the Board for overall ESG responsibility[73] Audit and Compliance - The Audit Committee reviewed the audited consolidated financial statements for the year ended 31 December 2021 and confirmed compliance with applicable accounting standards[167] - During the Year, the Audit Committee held four meetings with a 100% attendance rate[169] - The Remuneration Committee consists of one executive Director and three independent non-executive Directors, with a 100% attendance rate at meetings during the year[190][191] - The Board held two meetings during the year to review corporate governance policies, achieving a 100% attendance rate[197] - The Group's auditor confirmed that the continuing connected transactions for the year ended 31 December 2022 were in order[134]
中国医疗集团(08225) - 2022 - 年度财报